查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947950

依适应症、通路、最终用户和剂型分類的醋酸去氨加压素片市场－全球预测，2026-2032年

Desmopressin Acetate Tablets Market by Indication, Distribution Channel, End User, Formulation - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，醋酸去氨加压素片剂市值为 4.2591 亿美元，预计到 2026 年将成长至 4.4341 亿美元，到 2032 年将达到 5.6435 亿美元，复合年增长率为 4.10%。

关键市场统计数据
基准年 2025 4.2591亿美元
预计年份：2026年 4.4341亿美元
预测年份 2032 5.6435亿美元
复合年增长率 (%) 4.10%

简明临床概述，重点在于醋酸去氨加压素片的治疗作用、法规环境以及以病人为中心的考量。

醋酸去氨加压素片在内分泌治疗和症状治疗的交叉领域中占据独特的地位，尤其适用于需要控制抗利尿作用的情况。该化合物的药理特性使其在模拟血管加压素活性的同时，具有更高的安全性和耐受性，因此效用治疗多种疾病，从中枢性尿崩症到儿童夜间遗尿症。临床医生和护理团队依靠其可预测的抗利尿作用来减少夜间多尿和体液流失，而药学委员会在考虑其在治疗方案中的地位时，会评估其耐受性、给药便利性和长期依从性等因素。

配方创新、监管机构对上市后证据的重视、数位化辅助技术以及供应链可追溯性等变革正在重塑策略重点。

多种因素正在共同重塑醋酸去氨加压素片的市场格局，改变相关人员评估机会和风险的框架。製剂科学和缓释技术的进步重新引发了关于给药便利性和安全性范围的讨论，同时，对病患报告结果的日益关注正促使评估标准从传统的疗效终点转向包括依从性、生活品质和看护者负担在内的指标。

2025年关税变化和贸易政策转变如何促使製造商和买家采用动态筹资策略、增强供应链韧性并重新设计采购流程

2025年实施的关税和贸易政策调整为参与醋酸去氨加压素片生产、分销和采购的公司带来了新的营运挑战。进口关税和归类规则的变化影响了筹资策略，促使製造商重新评估供应商关係、区域製造地和库存计划，以降低成本和交货期的波动。这些趋势迫使采购部门重新评估其总到岸成本模型，并考虑近岸外包和供应商多元化，以降低跨境关税波动的风险。

以细分市场为重点的洞察揭示了适应症、通路、终端用户环境、剂量和製剂如何决定商业性和临床策略。

细分市场层面的细微差别揭示了临床需求、分销复杂性和给药策略之间的交集，从而影响产品定位和商业化重点。以适应症为基础的市场调查（中枢性尿崩症、原发性夜遗尿症、续发性夜遗尿症）突显了临床路径的差异：中枢性尿崩症、原发性夜遗尿症、继发性夜遗尿症）突显了临床路径的差异：中枢性尿崩症需要长期治疗并密切进行内分泌管理；续发性夜遗尿症需要以小儿科为中心的间歇性干预和以家庭为中心的依性疾病而需要对多因进行性病例而接受诊断行为的潜在病例。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势正在影响市场准入、监管方式和区域性商业化策略。

区域趋势对临床实务模式、监管预期和供应链产生了重大影响，并在各主要区域形成了不同的策略要务。在美洲，支付方框架、基层医疗处方习惯以及完善的门诊药房基础设施决定了醋酸去氨加压素片的取得和使用方式。该地区的相关人员普遍重视循证指南的实施以及与电子健康记录的整合，以便进行用药依从性监测。

品牌药产品组合、学名药供应商、特药製剂商和契约製造製造商的竞争格局和差异化路径

醋酸去氨加压素片在竞争格局中的地位并非由单一的创新巨头主导，而是由药物研发公司、学名药供应商、特药製剂商和契约製造商之间的相互作用决定。药物研发公司的产品系列通常着重于临床支援、风险管理专案和病患教育资源，以提高病患的长期治疗遵从性和安全性监测。另一方面，学名药生产商则在生产效率、供应可靠性和价格竞争力方面展开竞争，同时也投入资源准备证明生物等效性和品质一致性的监管文件。

切实可行的策略建议，重点在于配方创新、供应链韧性、通路专案支援、支付方合作以及数位化病患专案。

为了在醋酸去氨加压素片市场占据优势，行业领导企业应追求临床卓越性、供应稳定性和差异化的患者支持三者兼备。重要的是，应优先投资于配方改进，以解决依从性难题（例如，更便捷的给药方式和更轻的监测负担），同时透过系统的真实世界资料项目检验安全性。将研发工作与适应性监管策略结合，可以加快药物上市进程，并促进核准后数据的收集，从而满足监管机构和支付方的期望。

采用混合方法研究方法，结合深入的二手文献综述、有针对性的一手访谈、专家检验和严格的品管技术。

本报告的调查方法融合了结构化的二手研究、有针对性的一手研究以及严格的检验，以确保可靠的证据基础和可操作的研究结果。二手研究包括对同行评审的临床文献、监管文件和治疗指南的全面回顾，以及对药物警戒报告框架和药物专论的分析，以阐明药物的安全性和临床定位。这项基础性工作建构了临床和监管背景，为更深入的研究奠定了基础。

透过全面概述指导策略决策，重点在于阐述临床效用、製剂开发、监管严格性和供应链策略之间的相互作用。

总之，醋酸去氨加压素片仍是需要精确控制抗利尿作用的疾病的重要临床选择。然而，随着製剂技术的进步、监管的日益严格以及分销管道的创新，其应用环境也在不断变化。相关人员必须平衡临床需求（例如有效控制夜间症状和保障病人安全）与营运需求（例如稳健的采购、合规的生产和灵活的分销模式）。这两种需求促使人们需要製定整合策略，该策略应兼顾临床差异化、患者体验和供应链的稳健性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依适应症分類的醋酸去氨加压素片市场

  • 中枢性尿崩症
  • 原发性夜间遗尿症
  • 次发性遗尿

9. 醋酸去氨加压素片市场依通路划分

  • 在线的
  • 离线

第十章 依最终用户分類的醋酸去氨加压素片市场

  • 诊所
  • 居家照护
  • 医院

第十一章：醋酸去氨加压素片市场（以剂型划分）

  • 立即生效
  • 缓释製剂

第十二章 各地区去氨加压素醋酸盐片剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 醋酸去氨加压素片市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国去氨加压素醋酸盐片市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国醋酸去氨加压素片市场

第十六章 中国醋酸去氨加压素片市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Ferring Pharmaceuticals Inc.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FB6A0

The Desmopressin Acetate Tablets Market was valued at USD 425.91 million in 2025 and is projected to grow to USD 443.41 million in 2026, with a CAGR of 4.10%, reaching USD 564.35 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 425.91 million
Estimated Year [2026] USD 443.41 million
Forecast Year [2032] USD 564.35 million
CAGR (%) 4.10%

A concise and clinically focused introduction to desmopressin acetate tablets highlighting their therapeutic role, regulatory context, and patient-centered considerations

Desmopressin acetate tablets occupy a distinct niche at the intersection of endocrine therapy and symptomatic management, particularly where antidiuretic control is required. The compound's pharmacologic profile, which mimics vasopressin activity with an improved safety and tolerability margin, underpins its continued relevance for conditions ranging from central diabetes insipidus to pediatric nocturnal enuresis. Clinicians and care teams rely on its predictable antidiuretic effect to reduce nocturnal polyuria and fluid loss, while formulary committees evaluate tolerability, ease of administration, and long-term adherence characteristics when positioning it within therapeutic pathways.

Against this clinical backdrop, payer and provider stakeholders are increasingly focused on stewardship, real-world safety surveillance, and comparative effectiveness versus nonpharmacologic and alternative pharmacologic approaches. At the same time, formulation evolution and patient-centric delivery options have elevated adherence considerations, shaping how prescribers and caregivers discuss treatment goals. Regulatory authorities emphasize robust post-market monitoring for antidiuretic agents, prompting manufacturers and supply-chain partners to invest in compliance infrastructure and pharmacovigilance capabilities.

Consequently, an introduction to desmopressin acetate tablets must account for clinical utility, regulatory context, and evolving expectations around patient experience. Understanding these interrelated dimensions creates a foundation for strategic decisions in development, commercialization, and clinical practice alignment.

Transformative shifts driven by formulation innovation, regulatory emphasis on post-market evidence, digital adjuncts, and supply-chain traceability reshaping strategic priorities

The landscape for desmopressin acetate tablets is being reshaped by several converging forces that reframe how stakeholders evaluate opportunity and risk. Advances in formulation science and controlled-release technologies have enabled renewed conversations about dosing convenience and safety margins, while an emphasis on patient-reported outcomes has shifted evaluation criteria beyond traditional efficacy endpoints to include adherence, quality of life, and caregiver burden.

Simultaneously, regulatory frameworks are evolving to demand richer post-authorization safety data, driving manufacturers to integrate real-world evidence strategies into clinical development and commercial planning. Digital health adjuncts, including adherence monitoring and telehealth follow-ups, are increasingly integrated into treatment paradigms, enabling providers to better manage fluid balance and mitigate hyponatremia risk through closer monitoring and data-driven titration.

On the supply side, pharmaceutical manufacturers and contract partners are responding to heightened requirements for supply-chain traceability and manufacturing flexibility. This is altering sourcing strategies for active pharmaceutical ingredients and excipients, as well as accelerating adoption of quality-by-design approaches. Together, these shifts are creating a more complex but also more opportunity-rich environment for innovators, generics players, and specialty pharmacies to differentiate via formulation, support services, and integrated care models.

How 2025 tariff changes and trade policy shifts have compelled dynamic sourcing strategies, supply-chain resilience, and procurement re-engineering for manufacturers and buyers

The imposition of tariffs and trade policy adjustments in 2025 has introduced new operational realities for companies involved in the production, distribution, and procurement of desmopressin acetate tablets. Changes in import duties and classification rules have had implications for sourcing strategies, with manufacturers revisiting supplier relationships, regional manufacturing footprints, and inventory planning to mitigate cost and timing variability. These developments have prompted procurement teams to re-evaluate total landed cost models and to consider nearshoring or diversification of supplier bases to reduce exposure to cross-border tariff volatility.

Consequently, supply-chain partners and contract manufacturing organizations have increased focus on value-engineering and on incremental process optimizations to preserve margin and ensure continuity. In parallel, downstream distributors and pharmacies are adapting purchasing cadence and inventory buffers to smooth the impact of episodic cost shifts and regulatory customs requirements. Health systems and formularies are responding by tightening evaluation windows for alternative suppliers and by emphasizing contractual flexibility that can accommodate policy-driven price perturbations.

Taken together, the tariff environment of 2025 underscores the need for dynamic sourcing strategies, closer collaboration between commercial and supply functions, and scenario-based contingency planning to maintain access and affordability for patients reliant on desmopressin acetate therapy.

Segment-focused insights revealing how indication, distribution channels, end-user settings, dosage strengths, and formulation types determine commercial and clinical approaches

Segment-level nuances reveal where clinical demand, distribution complexity, and dosing strategies intersect to influence product positioning and commercialization focus. Based on Indication, market study across Central Diabetes Insipidus, Primary Nocturnal Enuresis, and Secondary Nocturnal Enuresis highlights divergent clinical pathways: central diabetes insipidus requires chronic management with close endocrine oversight, whereas primary nocturnal enuresis often involves episodic pediatric-focused interventions and family-centered adherence considerations, and secondary nocturnal enuresis demands investigation of underlying comorbidities and multidisciplinary care coordination.

Based on Distribution Channel, examination of Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy demonstrates how channel-specific dynamics shape access and patient experience; hospital pharmacies are oriented toward inpatient and specialty prescribing, online pharmacies offer convenience and subscription models that support long-term adherence, and retail pharmacies provide immediate fulfillment and points of counseling. Based on End User, segmentation into Clinics, Homecare, and Hospitals surfaces distinct utilization patterns: clinics and outpatient practices emphasize follow-up and titration protocols, homecare contexts prioritize ease of dosing and caregiver education, and hospital settings focus on acute management and safety monitoring.

Based on Dosage Strength, study across 0.1 Mg, 0.2 Mg, and 0.4 Mg informs dosing strategy development and packaging configurations that align with titration pathways and age- or weight-based regimens. Based on Formulation, differentiation between Immediate Release and Sustained Release captures trade-offs between onset of action and duration, with implications for nocturnal symptom control, dosing frequency, and risk mitigation efforts.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access, regulatory approaches, and localized commercialization tactics

Regional dynamics materially affect clinical practice patterns, regulatory expectations, and supply arrangements, creating differentiated strategic imperatives across major geographies. In the Americas, payer frameworks, primary care prescribing habits, and a robust outpatient pharmacy infrastructure shape how desmopressin acetate tablets are accessed and administered; stakeholders in this region commonly emphasize evidence-based guideline alignment and integration with electronic health records for adherence monitoring.

In Europe, Middle East & Africa, heterogeneous regulatory environments, variable reimbursement mechanisms, and distribution complexities require tailored regional strategies that account for country-level pricing policies, import controls, and differing clinical care models. Manufacturers and distributors often adopt segmented launch plans and targeted education initiatives to address the diversity of stakeholders and to ensure consistent pharmacovigilance practices across jurisdictions.

In Asia-Pacific, rapid urbanization, expanding private healthcare delivery, and increasing investment in specialty pharmaceuticals are influencing uptake patterns. Regional supply-chain hubs and manufacturing capacity expansions are also prominent, and strategic partnerships with local providers and distributors play a pivotal role in market access. Across all regions, local clinical guidelines, caregiver expectations, and health technology assessment processes must be navigated to ensure appropriate use and equitable patient access.

How originator portfolios, generic suppliers, specialty formulators, and contract manufacturers create a competitive ecosystem and differentiation pathways

Competitive positioning in the desmopressin acetate tablet landscape is defined less by a single dominant innovator and more by the interplay between originator formulations, generics suppliers, specialty formulators, and contract manufacturing providers. Innovator product portfolios typically emphasize clinical support, risk-management programs, and patient education resources that reinforce long-term therapy adherence and safety surveillance. Generics manufacturers, by contrast, compete on manufacturing efficiency, supply reliability, and price competitiveness while also investing in regulatory dossiers that demonstrate bioequivalence and consistent quality.

Specialty formulators and technology partners differentiate through extended-release platforms, novel excipient systems, and patient-friendly packaging that streamlines home administration. Contract manufacturing organizations and CDMOs play a strategic role by enabling capacity scale-up, offering flexible multi-source manufacturing, and implementing advanced quality systems to meet regional regulatory expectations. Service-oriented players, including specialty pharmacies and digital health vendors, further augment competitive dynamics by bundling adherence support, remote monitoring, and patient education into value propositions aimed at providers and payers.

Collectively, these company archetypes create a competitive ecosystem in which collaboration across development, manufacturing, and patient-support functions can be a critical source of differentiation and resilience.

Actionable strategic recommendations focused on formulation innovation, supply resiliency, channel-specific support, payer engagement, and digital-enabled patient programs

Industry leaders seeking to optimize their position in the desmopressin acetate tablets space should pursue a combination of clinical excellence, supply resiliency, and differentiated patient support. Prioritize investment in formulation refinements that address adherence challenges, such as dosing convenience and decreased monitoring burden, while simultaneously validating safety through structured real-world evidence programs. Aligning development efforts with adaptive regulatory strategies will help accelerate access pathways and facilitate post-authorization data collection that meets regulator and payer expectations.

Operationally, diversify supplier networks and consider regional manufacturing or tolling arrangements to reduce exposure to trade-policy shocks and tariff-driven cost variability. Strengthen relationships across distribution channels by deploying channel-specific support programs-hospital-oriented clinical liaisons, online pharmacy subscription models, and retail pharmacist education-to ensure consistent messaging and adherence reinforcement. Collaborate with payers and health systems to design value-based arrangements or outcomes-linked programs that reflect real-world benefits and patient-centric outcomes.

Finally, embed digital tools into patient support ecosystems to enable adherence monitoring, remote titration guidance, and timely safety surveillance. By integrating clinical, operational, and commercial levers, leaders can build resilient programs that respond to evolving regulatory demands and shifting care delivery preferences.

A mixed-methods research approach combining thorough secondary review, targeted primary interviews, expert validation, and robust quality-control practices

The report's methodology blends structured secondary research with targeted primary engagement and rigorous validation to ensure a robust evidence base and actionable insights. Secondary research encompasses comprehensive review of peer-reviewed clinical literature, regulatory documents, and therapeutic guidelines, supplemented by analysis of pharmacovigilance reporting frameworks and drug monographs to characterize safety and clinical positioning. This foundational work establishes the clinical and regulatory context upon which more granular inquiries are built.

Primary research includes interviews with clinicians, pharmacy directors, procurement experts, and patient advocacy representatives to surface real-world practice patterns, unmet needs, and adoption barriers. These qualitative inputs are triangulated with input from supply-chain and manufacturing specialists to capture operational constraints and sourcing preferences. Data validation steps involve cross-referencing primary insights with independent secondary sources and running iterative expert review panels to reconcile divergent perspectives and ensure interpretative rigor.

Throughout, quality control mechanisms-such as transparent documentation of data sources, audit trails for interview synthesis, and standardized templates for evidence grading-support reproducibility and credibility. This mixed-methods approach ensures that findings are grounded in both clinical realities and commercial pragmatism, enabling stakeholders to translate evidence into strategy.

Concluding synthesis emphasizing the interplay of clinical utility, formulation development, regulatory rigor, and supply-chain strategies to guide strategic decision-making

In conclusion, desmopressin acetate tablets remain a clinically important option for conditions that require precise antidiuretic control, while the broader environment around their use is evolving through formulation advances, regulatory rigor, and channel innovation. Stakeholders must balance clinical imperatives-such as effective nocturnal symptom control and patient safety-with operational necessities like resilient sourcing, compliant manufacturing, and adaptive distribution models. These dual imperatives drive the need for integrated strategies that account for clinical differentiation, patient experience, and supply-chain robustness.

Moving forward, organizations that invest in evidence generation, patient-centric delivery, and collaborative supply arrangements will be better positioned to navigate regional complexities and policy shifts. By combining clinical insight with operational discipline and targeted commercialization tactics, manufacturers and healthcare partners can improve patient outcomes while sustaining access and affordability. The synthesis of clinical, regulatory, and commercial perspectives presented here provides a practical foundation for decision-makers preparing to act in a dynamic therapeutic and policy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Desmopressin Acetate Tablets Market, by Indication

  • 8.1. Central Diabetes Insipidus
  • 8.2. Primary Nocturnal Enuresis
  • 8.3. Secondary Nocturnal Enuresis

9. Desmopressin Acetate Tablets Market, by Distribution Channel

  • 9.1. Online
  • 9.2. Offline

10. Desmopressin Acetate Tablets Market, by End User

  • 10.1. Clinics
  • 10.2. Homecare
  • 10.3. Hospitals

11. Desmopressin Acetate Tablets Market, by Formulation

  • 11.1. Immediate Release
  • 11.2. Sustained Release

12. Desmopressin Acetate Tablets Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Desmopressin Acetate Tablets Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Desmopressin Acetate Tablets Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Desmopressin Acetate Tablets Market

16. China Desmopressin Acetate Tablets Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accord Healthcare Ltd.
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Apotex Inc.
  • 17.8. Aurobindo Pharma Limited
  • 17.9. Cipla Limited
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. Endo International plc
  • 17.12. Ferring Pharmaceuticals Inc.
  • 17.13. Fresenius Kabi AG
  • 17.14. Glenmark Pharmaceuticals Limited
  • 17.15. Hikma Pharmaceuticals PLC
  • 17.16. Lupin Limited
  • 17.17. Mylan N.V.
  • 17.18. Novartis AG
  • 17.19. Pfizer Inc.
  • 17.20. Sandoz International GmbH
  • 17.21. Strides Pharma Science Limited
  • 17.22. Sun Pharmaceutical Industries Ltd.
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY PRIMARY NOCTURNAL ENURESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY PRIMARY NOCTURNAL ENURESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY PRIMARY NOCTURNAL ENURESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SECONDARY NOCTURNAL ENURESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SECONDARY NOCTURNAL ENURESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SECONDARY NOCTURNAL ENURESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 83. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)